Glenview Trust co Has $2.19 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Glenview Trust co raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 3,071 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Glenview Trust co’s holdings in Regeneron Pharmaceuticals were worth $2,188,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $26,000. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $36,000. Finally, Private Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.0 %

Shares of Regeneron Pharmaceuticals stock opened at $666.87 on Monday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The stock has a market cap of $72.91 billion, a PE ratio of 17.42, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The business has a fifty day simple moving average of $694.91 and a 200 day simple moving average of $831.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the business posted $11.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on REGN shares. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Finally, Bank of America reissued an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.